# Extension Study Evaluating Antibody Persistence and Safety, Tolerability and Immunogenicity of a Booster Dose of Novartis rMenB±OMV NZ Vaccine in Healthy UK Children Who Previously Received Three Doses of the Same Vaccine

> **NCT01026974** · PHASE2 · COMPLETED · sponsor: **Novartis Vaccines** · enrollment: 120 (actual)

## Conditions studied

- Meningococcal Disease

## Interventions

- **BIOLOGICAL:** rMenB
- **BIOLOGICAL:** rMenB+OMV NZ

## Key facts

- **NCT ID:** NCT01026974
- **Lead sponsor:** Novartis Vaccines
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-02
- **Primary completion:** 2010-09
- **Final completion:** 2012-05
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2014-10-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01026974

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01026974, "Extension Study Evaluating Antibody Persistence and Safety, Tolerability and Immunogenicity of a Booster Dose of Novartis rMenB±OMV NZ Vaccine in Healthy UK Children Who Previously Received Three Doses of the Same Vaccine". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01026974. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*